An epirubicin/paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen

Haematologica

Volumn 84, Issue 10, 1999, Pages 924-929

  Zibera, Carlo ^b   Pedrazzoli, Paolo ^c   Ponchio, Luisa ^c   Gibelli, Nadia ^c   Lanza, Annalisa ^c   Da Prada, Gian Antonio ^c   Zambelli, Alberto ^c   Perotti, Cesare ^a   Torretta, Lorella ^a   Salvaneschi, Laura ^a   Della Cuna, Gioacchino Robustelli ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IRCCS   (Italy)

^c NONE

Author keywords

Apheresis; Epirubicin; High dose chemotherapy; Paclitaxel; Peripheral blood progenitors

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PACLITAXEL; THIOTEPA; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CLONOGENESIS; COLONY FORMING CELL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; AUTOTRANSPLANTATION; BLOOD; BREAST TUMOR; CELL CLONE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; STEM CELL MOBILIZATION; TIME;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLONE CELLS; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKAPHERESIS; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033205035     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89:2233-58.
2. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353-7.
3. Caballero MD, Vazquez L, Barragan JM, et al.Randomized study of filgrastim versus molgramostim after peripheral stem cell transplant in breast cancer. Haematologica 1998; 83:514-8.
4. Bezwoda WR, Seymour L, Dansey RD, et al. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13:2483-9.
5. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15:1870-9.
6. Gianni L, Munzone E, Capri C, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13:2688-99.
7. Sledge GWJr, Robert N, Sparano JA, et al. Cooperative Oncology group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 1995; 22 (suppl. 6):105-8.
8. Pedrazzoli P, Perotti C, Da Prada GA, et al. Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. Br J Cancer 1997; 75:1368-72.
9. Bengala C, Pazzagli I, Tibaldi C, et al. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte colony-stimulating factor administered to patients with metastatic breast carcinoma. Cancer 1998; 82:867-73.
10. Torretta L, Perotti C, Dornini G, et al. Circulating progenitor cell collection: experience from 275 leukaphereses in various malignancies and healthy donors. Haematologica 1996; 81:208-15.
11. Tyer CL, Vredenburgh JJ, Heimer M, Peters WP, Bast RC. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 1996; 2:81-6.
12. Battaglia M, Pedrazzoli P, Palermo B, et al. Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: a new sensitive one step method without false positive results. Bone Marrow Transplant 1998; 22:693-8.
13. Ponchio L, Eaves C, Hogge D, et al. Both cycling and noncycling primitive progenitors continue to be mobilized during the leukapheresis of patients treated with chemotherapy and G-CSF. Br J Haematol 1997; 99: 394-402.
14. Hogge D, Fanning S, Bockhold K, et al. Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. Br J Haematol 1997; 96:790-800.
15. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86:3961-9.
16. Zijlmans JMJM, Visser JWM, Laterweer L, et al. The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. PNAS 1998; 95:725-9.
17. Breems DA, Van Hennik PB, Kusadasi N, et al. Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood, 1996; 87:5370-8.
18. Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91:3148-55.
19. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13:2547-55.
20. Vahadat LT, Papadopulos K, Balmaceda C, et al. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res 1998; 4:1689-95.
21. Watts MJ, Sullivan AM, Ings SJ, et al. Evaluation of clinical scale CD34+ cell purification: Experience of 71 immunoaffinity column procedures. Bone Marrow Transplant 1997, 20:157-62.
22. Champlin R. Purging: the separation of normal from malignant cells for autologous transplantation. Transfusion 1996; 36:910-8.
23. Chapple P, Prince HM, Quinn M, et al. Peripheral blood CD34+ cell count reliably predicts autograft yield. Bone Marrow Transplant 1998; 22:125-30.
24. Benjamin RJ, Linsley L, Fountain D, et al. Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield. Transfusion 1997; 37:79-85.
25. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82:2605-10.
26. Weaver CH, Moss T, Schwartzberg LS, et al. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 1998; 21:1117-24.
27. Gluck S, Ross AA, Layton TJ, et al. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. Biol Blood Marrow Transplant 1997; 3:316-23.